Calquence (Acalabrutinib) is a prescription medication used in the treatment of certain blood cancers, specifically adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It belongs to a class of drugs known as Bruton's tyrosine kinase (BTK) inhibitors. By blocking BTK, Calquence helps to stop the growth and spread of cancer cells. It is administered orally in capsule form. As with any cancer therapy, it is important for patients to discuss the potential benefits and risks of using Calquence with their healthcare provider.
When using CALQUENCE, it's crucial to take certain precautions to ensure your safety and the effectiveness of the medication. One important consideration is whether you can drive or operate heavy machinery; CALQUENCE may cause side effects such as dizziness or weakness, which could impair your ability to perform these activities safely. Common side effects include headache, diarrhea, muscle and joint pain, and fever, while rare side effects might involve more serious conditions such as bleeding problems or infections. It's imperative to follow your doctor's instructions closely and to read the label that comes with the medicine to understand how to use it properly. Additionally, always inform your doctor about any other medications you are taking, as CALQUENCE can interact with other drugs, potentially leading to adverse effects. Adhering to these guidelines will help minimize risks and maximize the benefits of your treatment.